Project Grant H8G48682

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $10,631,760 Cooperative Agreement to the Pan American Health Organization (PAHO) on May 1, 2024 through the Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects program (CFDA 93.185). This funding supports comprehensive public health initiatives across the Americas to enhance vaccination strategies, disease surveillance, epidemiological understanding, and...

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,994,888 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Triangle Institute (RTI International) to establish and maintain the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (REVAMPP) Coordinating and Data Sharing Center (CDSC). The CDSC will coordinate and facilitate a network of six to eight research centers...

This Cooperative Agreement award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will test a novel vaccine approach designed to generate broad and durable antibody responses against SARS-CoV-2. The $2,870,428 award, with a performance period from May 2024 to April 2029, will evaluate the safety and immunogenicity of a T follicular helper (Tfh)-targeting vaccine adjuvant, "S3",...

The Hawaii Department of Health has been awarded a $4,018,665 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) under the Public Health Emergency Response: Cooperative Agreement for Emergency Response (CFDA 93.354) program. The funding will support the establishment and maintenance of a workgroup within the department to increase vaccination rates in Hawaii, with a specific focus on populations disproportionately affected by MPOX. Key activities include working with...

This $442,478 Project Grant awarded by the National Science Foundation under the Social, Behavioral, and Economic Sciences program (CFDA 47.075) supports a multi-modal study on factors influencing vaccine decision-making, particularly in underserved communities. The research team from the University of California, Los Angeles (UCLA) will examine how local models of illness, medical mistrust, sociodemographic variables, and social learning shape vaccination beliefs and practices. The project...

This $999,904 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (CFDA 93.323) program supports the University of Rochester in implementing its "Trusted School Messengers Promoting Non-Mandated Vaccination" project. The project aims to enhance public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases by leveraging trusted school...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $310,644 to the Children's Research Institute to identify factors influencing parental hesitancy towards seasonal respiratory vaccines (SRVs) for children in the post-COVID-19 pandemic era. The project aims to: 1) determine the key determinants of parental SRV hesitancy, 2) understand pediatricians'...

This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totaling $737,761 and spanning from Aug 1, 2024 to Jun 30, 2029. The project aims to enhance HIV prevention through a vaccine approach that promotes durable immunity by inducing robust CD4 T follicular helper (Tfh) cells. The research will examine whether a vaccine platform tailored to promote Tfh1 cell differentiation, in...

This $228,825 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research conducted by New York University School of Medicine to develop an improved HIV vaccine. The objective is to synergize the effects of neutralizing and non-neutralizing antibodies targeting the HIV viral spike apex, building on insights from effective COVID-19 vaccines. Specifically, the project will: 1) Design and...